Healthcare Professionals
What is Caphosol®?
Caphosol® is an electrolyte solution for the prevention and treatment of oral mucositis.1 Caphosol® is indicated for dryness of the mouth and oropharynx regardless of the cause or whether the conditions are temporary or permanent.1 Caphosol® can also be used as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy.1
Caphosol® is designed to moisten, lubricate and clean the oral cavity including the mucosa of mouth, tongue and oropharynx.1Additionally, Caphosol® helps maintain the integrity of the oral cavity.2
Who can use Caphosol®?
Caphosol® can be used by patients receiving radiation or high-dose chemotherapy to prevent and treat oral mucositis. Caphosol® can also be used by patients suffering from dryness of the mouth and oropharynx regardless of the cause or whether the conditions are temporary or permanent.1
How can Caphosol® help patients with oral mucositis?
Caphosol® contains high concentrations of calcium and phosphate ions. Calcium and phosphate are important in maintaining a healthy oral cavity. Caphosol® can help patients with oral mucositis by:
- Facilitating chewing and speaking
- Loosening tough mucus
- Preventing mucous membranes sticking together
- Relieving dryness of the oral mucosa is associated with amelioration of pain
The safety and efficacy of Caphosol® in treating oral mucositis has been clinically demonstrated.2 Caphosol® was shown to:
- Reduce the duration of oral mucosisits2
- Reduce the duration of pain associated with oral mucositis2
- Reduce the requirement for opioid analgesics2
Caphosol® has also been shown to have a clinically significant impact on the occurrence and severity of oral mucosits in an open-label observational registry.3
Through preventing and treating oral mucositis associated with cancer therapies, the risk of interrupting cancer treatment is reduced.
References
Note: All the references are available on request to EUSA Pharma
1. Caphosol®Product information. EUSA Pharma (Europe) Limited, Nov 2008
2. Papas AS et al. Bone Marrow Transplant 2003;31:705–712
3. Haas M et al. 50th ASTRO congress 2008; abstract 2530
